Entrada Therapeutics, Inc.
NASDAQ:TRDA
Overview | Financials
| Company Name | Entrada Therapeutics, Inc. |
| Symbol | TRDA |
| Currency | USD |
| Price | 5.28 |
| Market Cap | 200,835,782 |
| Dividend Yield | 0% |
| 52-week-range | 4.93 - 21.79 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Dipal Doshi |
| Website | https://www.entradatx.com |
An error occurred while fetching data.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD







